RESUMO
Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.
Assuntos
Antivirais/uso terapêutico , Cloroquina/uso terapêutico , Infecções por Coronavirus/tratamento farmacológico , Pneumonia Viral/tratamento farmacológico , Antivirais/efeitos adversos , Antivirais/farmacologia , Antivirais/normas , Betacoronavirus/efeitos dos fármacos , COVID-19 , China , Cloroquina/efeitos adversos , Cloroquina/farmacologia , Cloroquina/normas , Ensaios Clínicos como Assunto/normas , Humanos , Hidroxicloroquina/efeitos adversos , Hidroxicloroquina/farmacologia , Hidroxicloroquina/normas , Hidroxicloroquina/uso terapêutico , Pandemias , SARS-CoV-2Assuntos
Antimaláricos/normas , Resistência Microbiana a Medicamentos , Malária Falciparum/tratamento farmacológico , Plasmodium falciparum , Antimaláricos/uso terapêutico , Artemisininas/normas , Artemisininas/uso terapêutico , Cloroquina/normas , Cloroquina/uso terapêutico , Combinação de Medicamentos , Quimioterapia Combinada , Humanos , Pirimetamina/normas , Pirimetamina/uso terapêutico , Sulfadoxina/normas , Sulfadoxina/uso terapêuticoRESUMO
The objective of this study was to evaluate the feasibility of 10 commonly used active pharmaceutical ingredients (APIs) compounded in oral suspensions using an internationally used suspending vehicle (SyrSpend(®) SF PH4 liquid): (i) amlodipine, (as besylate) 1.0mg/mL; (ii) chloroquine phosphate,15.0 mg/mL; (iii) dapsone, 2.0 mg/mL; (iv) phenytoin, 15.0 mg/mL; (v) pyridoxine hydrochloride, 50.0 mg/mL; (vi) sulfadiazine, 100.0 mg/mL; (vii) sulfasalazine, 100.0 mg/mL; (viii) tetracycline hydrochloride, 25.0 mg/mL; (ix) trimethoprim, 10.0 mg/mL; and (x) zonisamide, 10.0 mg/mL. All suspensions were stored both at controlled refrigeration (2-8 °C) and controlled room temperature (20-25 °C). Feasibility was assessed by measuring the percent recovery at varying time points throughout a 90-day period. API quantification was performed by high-performance liquid chromatography (HPLC-UV), via a stability-indicating method. Given the percentage of recovery of the APIs within the suspensions, the expiration date of the final products (API+vehicle) was at least 90 days for all suspensions with regard to both the controlled temperatures. This suggests that the vehicle is stable for compounding APIs from different pharmacological classes.
Assuntos
Estabilidade de Medicamentos , Armazenamento de Medicamentos/métodos , Suspensões/análise , Suspensões/normas , Administração Oral , Anlodipino/análise , Anlodipino/normas , Cloroquina/análogos & derivados , Cloroquina/análise , Cloroquina/normas , Cromatografia Líquida de Alta Pressão/métodos , Dapsona/análise , Dapsona/normas , Armazenamento de Medicamentos/normas , Estudos de Viabilidade , Concentração de Íons de Hidrogênio , Isoxazóis/análise , Isoxazóis/normas , Fenitoína/análise , Fenitoína/normas , Piridoxina/análise , Piridoxina/normas , Sulfadiazina/análise , Sulfadiazina/normas , Sulfassalazina/análise , Sulfassalazina/normas , Tetraciclina/análise , Tetraciclina/normas , Trimetoprima/análise , Trimetoprima/normas , ZonisamidaRESUMO
BACKGROUND: Poor-quality life-saving medicines are a major public health threat, particularly in settings with a weak regulatory environment. Insufficient amounts of active pharmaceutical ingredients (API) endanger patient safety and may contribute to the development of drug resistance. In the case of malaria, concerns relate to implications for the efficacy of artemisinin-based combination therapies (ACT). In Papua New Guinea (PNG), Plasmodium falciparum and P. vivax are both endemic and health facilities are the main source of treatment. ACT has been introduced as first-line treatment but other drugs, such as primaquine for the treatment of P. vivax hypnozoites, are widely available. This study investigated the quality of antimalarial drugs and selected antibiotics at all levels of the health facility supply chain in PNG. METHODS AND FINDINGS: Medicines were obtained from randomly sampled health facilities and selected warehouses and hospitals across PNG and analysed for API content using validated high performance liquid chromatography (HPLC). Of 360 tablet/capsule samples from 60 providers, 9.7% (95% CI 6.9, 13.3) contained less, and 0.6% more, API than pharmacopoeial reference ranges, including 29/37 (78.4%) primaquine, 3/70 (4.3%) amodiaquine, and one sample each of quinine, artemether, sulphadoxine-pyrimethamine and amoxicillin. According to the package label, 86.5% of poor-quality samples originated from India. Poor-quality medicines were found in 48.3% of providers at all levels of the supply chain. Drug quality was unrelated to storage conditions. CONCLUSIONS: This study documents the presence of poor-quality medicines, particularly primaquine, throughout PNG. Primaquine is the only available transmission-blocking antimalarial, likely to become important to prevent the spread of artemisinin-resistant P. falciparum and eliminating P. vivax hypnozoites. The availability of poor-quality medicines reflects the lack of adequate quality control and regulatory mechanisms. Measures to stop the availability of poor-quality medicines should include limiting procurement to WHO prequalified products and implementing routine quality testing.
Assuntos
Antimaláricos/análise , Medicamentos Biossimilares/análise , Malária Falciparum/tratamento farmacológico , Malária Vivax/tratamento farmacológico , Amodiaquina/análise , Amodiaquina/normas , Amodiaquina/uso terapêutico , Amoxicilina/análise , Amoxicilina/normas , Amoxicilina/uso terapêutico , Antimaláricos/normas , Antimaláricos/uso terapêutico , Artemeter , Artemisininas/análise , Artemisininas/normas , Artemisininas/uso terapêutico , Medicamentos Biossimilares/normas , Medicamentos Biossimilares/uso terapêutico , Cloroquina/análise , Cloroquina/normas , Cloroquina/uso terapêutico , Resistência a Medicamentos , Instalações de Saúde , Humanos , Papua Nova Guiné , Primaquina/análise , Primaquina/normas , Primaquina/uso terapêutico , Controle de Qualidade , Quinina/análise , Quinina/normas , Quinina/uso terapêuticoRESUMO
Malaria is the biggest killer of African children, yet it is cheaply preventable and curable with insecticides spraying, impregnated bednets and effective drugs. This study aimed to evaluate the quality of Chloroquine (CQ) tablets available in selected African countries. Twenty-six samples of antimalarial CQ tablet of 100, 150 and 250 mg were collected from 12 African countries and evaluated for their quality in the Drugs Quality Control Laboratory of Rabat, Morocco. The identification and dosage of active pharmaceutical ingredients in the tablets, dissolution rate, hardness and the friability of CQ tablets were performed according to the United States Pharmacopeia (USP) and European Pharmacopoeia (Eur.Ph.) recommended methods. The results showed that 7·7% of the sampled CQ tablets available in Burkina Faso were of low quality. Failure in dissolution profile was found in 50% of CQ tablets sampled from Benin, Burkina Faso, Comoros Union, Mali and Senegal. The findings showed poor quality of CQ tablets available in the African market. This problem may affect the efforts to control malaria in Africa. Efficient regulatory systems of drugs quality control should be implemented.
Assuntos
Antimaláricos/normas , Cloroquina/normas , África , Antimaláricos/administração & dosagem , Antimaláricos/química , Cloroquina/administração & dosagem , Cloroquina/química , Composição de Medicamentos/normas , Testes de Dureza/métodos , Humanos , Projetos Piloto , Vigilância de Produtos Comercializados/métodos , Controle de Qualidade , Solubilidade , Comprimidos/normasRESUMO
INTRODUCTION: The emergence of drug resistance is one of the main problems concerning malaria treatment. The use of counterfeit and/or substandard antimalarial drugs can contribute to the development of parasite resistance. Thus, the aim of this study was to evaluate the quality of antimalarial drugs distributed in Brazil. METHODS: Samples containing chloroquine phosphate, mefloquine hydrochloride, primaquine phosphate, and quinine sulfate tablets were delivered to the Rio de Janeiro central storeroom (CENADI), state storerooms (SS), and Basic Health Units (BHUs) in the north region of Brazil - a total of 10 sample sets. After 5 months of storage, the samples were collected, and in vitro quality control analyses according to official and published methods were performed. RESULTS: Inadequate drug storage conditions were found in two SS and in all BHUs evaluated. There were no quality deviations found in the chloroquine samples. The quinine samples exhibited weight variation above the allowed limits. The primaquine samples were found to have packaging deficiency. The release of mefloquine in samples from some regions showed a statistically significant difference when compared with the CENADI samples. CONCLUSIONS: It is important to periodically evaluate the quality and storage conditions of essential drugs. The quality deviations found with the primaquine and quinine samples are not related to storage conditions and must be addressed urgently. The decreased mefloquine release from tablets is related to formulation problems or influenced by inadequate storage conditions, prompting further investigation. Even with the mentioned problems, the samples would probably not contribute to resistant parasite selection.
Assuntos
Antimaláricos/normas , Armazenamento de Medicamentos/normas , Medicamentos Essenciais/normas , Brasil , Cloroquina/normas , Cromatografia Líquida de Alta Pressão , Humanos , Mefloquina/normas , Primaquina/normas , Controle de Qualidade , Quinina/normasRESUMO
INTRODUCTION: The emergence of drug resistance is one of the main problems concerning malaria treatment. The use of counterfeit and/or substandard antimalarial drugs can contribute to the development of parasite resistance. Thus, the aim of this study was to evaluate the quality of antimalarial drugs distributed in Brazil. METHODS: Samples containing chloroquine phosphate, mefloquine hydrochloride, primaquine phosphate, and quinine sulfate tablets were delivered to the Rio de Janeiro central storeroom (CENADI), state storerooms (SS), and Basic Health Units (BHUs) in the north region of Brazil - a total of 10 sample sets. After 5 months of storage, the samples were collected, and in vitro quality control analyses according to official and published methods were performed. RESULTS: Inadequate drug storage conditions were found in two SS and in all BHUs evaluated. There were no quality deviations found in the chloroquine samples. The quinine samples exhibited weight variation above the allowed limits. The primaquine samples were found to have packaging deficiency. The release of mefloquine in samples from some regions showed a statistically significant difference when compared with the CENADI samples. CONCLUSIONS: It is important to periodically evaluate the quality and storage conditions of essential drugs. The quality deviations found with the primaquine and quinine samples are not related to storage conditions and must be addressed urgently. The decreased mefloquine release from tablets is related to formulation problems or influenced by inadequate storage conditions, prompting further investigation. Even with the mentioned problems, the samples would probably not contribute to resistant parasite selection.
INTRODUÇÃO: O aparecimento de resistência aos medicamentos é um dos maiores problemas do tratamento da malária. O uso de medicamentos falsos e/ou de má qualidade pode contribuir para o desenvolvimento de resistência no parasita. Este estudo tem por objetivo avaliar a qualidade dos medicamentos antimaláricos distribuídos no Brasil. MÉTODOS: Amostras contendo comprimidos de difosfato de cloroquina, cloridrato de mefloquina, difosfato de primaquina e sulfato de quinina foram enviadas ao almoxarifado central na Cidade do Rio de Janeiro (CENADI), almoxarifados estaduais (SS) e Unidades Básicas de Saúde (UBS) nos estados da região norte do Brasil, totalizando dez amostras. Após cinco meses de armazenamento, as amostras foram coletadas e analisadas segundo métodos oficiais e da literatura. RESULTADOS: Foram encontradas condições inadequadas de armazenamento de medicamentos em duas SS e em todas as UBS avaliadas. Não foram encontrados problemas de qualidade com as amostras de cloroquina. As amostras de quinina apresentaram variação de peso acima dos limites permitidos. Amostras de primaquina foram encontradas com problemas na embalagem. A cedência de mefloquina de comprimidos, em algumas regiões, apresentou diferença estatisticamente significativa quando comparada com a amostra do CENADI. CONCLUSÕES: É importante avaliar, periodicamente, a qualidade e as condições de armazenamento de medicamentos essenciais. Desvios de qualidade encontrados com as amostras de primaquina e quinina não estão relacionados às condições de armazenamento e devem ser corrigidos urgentemente. O decréscimo na cedência de mefloquina dos comprimidos está relacionado com a formulação ou foi influenciada por condições de armazenamento inadequadas, necessitando de uma investigação posterior. Apesar dos problemas mencionados, as amostras provavelmente não contribuiriam para a seleção de parasitas resistentes.
Assuntos
Humanos , Antimaláricos/normas , Armazenamento de Medicamentos/normas , Medicamentos Essenciais/normas , Brasil , Cromatografia Líquida de Alta Pressão , Cloroquina/normas , Mefloquina/normas , Primaquina/normas , Controle de Qualidade , Quinina/normasRESUMO
OBJECTIVE: Drug quality may be poor in many regions of the world. Our first aim was to verify whether the dose of the active compounds in various antimalarial medicines on the market in East Congo conforms to the quality requirements of the European Pharmacopoeia (Ph. Eur.). The second aim was to check the extent to which simple methods of analysis could be used to evaluate drug quality. METHODS: The formulations analysed included tablets, injections and syrups of chloroquine (CQ), quinine, sulfadoxine-pyrimethamine (SP) and proguanil. Ultraviolet (UV) spectrophotometry was used to quantify CQ and quinine in tablets and injections. Thin layer chromatography was used to identify the preservative(s) in the syrups. As the drug form (base or salt) in the tablets, is rarely declared, the estimated dose was calculated using both forms. High-performance liquid chromatography (HPLC) was used to check for assay interference and for measuring SP combinations. RESULTS AND DISCUSSION: When the dose declaration on the label was assumed to be of the salt form, 33% of CQ batches were underdosed and two of eight batches of quinine were underdosed by about 25% and 15% respectively. When the base form was assumed, only one batch of CQ tablets conformed. The underdosed batches contained about 50-66% of the claimed amount for CQ. The dose of quinine in the different batches of tablets was in the range 62-86%. For the CQ syrup, interference by the preservative Nipagin, confirmed by HPLC-UV, was observed with UV-spectrophotometry at 257 nm but not at 342 nm. The results for CQ syrup using UV-spectrophotometry at 342 nm and HPLC-UV at 257 nm were comparable and showed compliance with the European Pharmacopoeia limits of 95-105%. One of two batches of CQ injections and one of four batches of quinine injections were overdosed by about 14% and 8% respectively. The SP tablets were analysed by using HPLC-UV only. All five batches were underdosed in sulfadoxine (91-94%) but still met the United States Pharmacopeial (USP) limit of 90-110%. Two batches were slightly overdosed in pyrimethamine (106% and 108% respectively) while one batch contained neither active ingredient. The one batch of proguanil analysed, met the Ph. Eur. quality requirement (98.7%). CONCLUSION: Simple methods of analysis like UV-spectrophotometry can be used to check drug quality routinely. A substantial proportion of the antimalarial drugs sold on the Congo DR market is of poor quality. Some batches contain little or no drug. This is a serious threat to public health in the region of Congo DR.
Assuntos
Cloroquina/normas , Vigilância de Produtos Comercializados/métodos , Proguanil/normas , Pirimetamina/normas , Quinina/normas , Sulfadoxina/normas , Antimaláricos/normas , Cromatografia Líquida de Alta Pressão , República Democrática do Congo , Aprovação de Drogas , Combinação de Medicamentos , Indústria Farmacêutica/métodos , Indústria Farmacêutica/normas , Preparações Farmacêuticas/análise , Preparações Farmacêuticas/normas , Vigilância de Produtos Comercializados/normas , Controle de Qualidade , ComprimidosRESUMO
BACKGROUND: Malaria has always been a major public health problem in Yemen. Several studies in developing countries have demonstrated ineffective and poor quality drugs including antimalarials. Therefore, quality assessment of antimalarial drugs is of crucial importance. This study aimed to assess the quality of antimalarials (chloroquine and sulfadoxine/pyrimethamine) available in Yemen and to determine whether the quality of these products was related to the level of the distribution chain at which the samples were collected or related to the manufacturers. METHODS: Four samples from each antimalarial product were collected from each of the various levels of the distribution chain. One sample was kept with the research team. Two were tested at Sana'a and Aden Drug Quality Control Laboratories. The fourth was sent to the Centre for Quality Assurance of Medicines in Potchefstroom, South Africa, for analysis. Quality indicators measured were the content of the active ingredient and dissolution rate (for tablets only) in comparison to standard specifications for these products in the relevant pharmacopoeia. RESULTS: The results identified several problems of sub-standard products within the drug distribution chain. They included high and low failures in ingredient content for chloroquine tablets and chloroquine syrup. There was some dissolution failure for chloroquine tablets, and high sulfadoxine/pyrimethamine tablets dissolution failures. Failures with the dissolution of the pyrimethamine were found at most of the collection points. No clear relationship neither between the quality products and the level of the distribution chain, nor between locally manufactured and imported products was observed. CONCLUSION: There are sub-standard antimalarial products circulating within the drug distribution chains in the country, which will have serious implications on the reduced therapeutic effectiveness and on the development of drug resistance. This appears to be due to non-compliance with Good Manufacturing Practice guidelines by manufacturers in the production of the antimalarials.
Assuntos
Antimaláricos/provisão & distribuição , Antimaláricos/normas , Cloroquina/provisão & distribuição , Cloroquina/normas , Pirimetamina/provisão & distribuição , Pirimetamina/normas , Sulfadoxina/provisão & distribuição , Sulfadoxina/normas , Antimaláricos/química , Cloroquina/química , Formas de Dosagem , Combinação de Medicamentos , Vigilância de Produtos Comercializados , Pirimetamina/química , Controle de Qualidade , Sulfadoxina/química , IêmenRESUMO
BACKGROUND & OBJECTIVES: The aim of the present study is to investigate the physicochemical equivalence of seven brands of tablets containing chloroquine phosphate, an antimalarial purchased from different retail pharmacy outlets. METHODS: The quality and physicochemical equivalence of seven different brands of chloroquine phosphate tablets were assessed. The assessment included the evaluation of uniformity of weight, friability, crushing strength, disintegration and dissolution tests as well as chemical assay of the tablets. RESULTS: All the seven brands of the tablets passed the British Pharmacopoeia (BP) standards for uniformity of weight, disintegration and crushing strength. One of seven brands failed the friability test. One of the brands did not comply with the standard assay of content of active ingredients. Dissolution test passes the pharmacopoeial standards for chloroquine phosphate tablets. There were no significant differences in the amounts of chloroquine phosphate released from the different brands. INTERPRETATION & CONCLUSION: Out of the seven brands of anti-malarial chloroquine phosphate tablets only one brand fails to meet BP quality specifications which shows constant market monitoring of new products to ascertain their equivalency to pharmacopoeial standards.
Assuntos
Antimaláricos/análise , Cloroquina/análise , Animais , Antimaláricos/química , Antimaláricos/normas , Cloroquina/química , Cloroquina/normas , Humanos , Controle de Qualidade , ComprimidosAssuntos
Antimaláricos/economia , Antimaláricos/uso terapêutico , Agências Internacionais , Malária/tratamento farmacológico , Imperícia , Organização Mundial da Saúde , Altruísmo , Antimaláricos/normas , Cloroquina/economia , Cloroquina/normas , Cloroquina/uso terapêutico , Custos de Medicamentos/estatística & dados numéricos , Organização do Financiamento/economia , Saúde Global , Humanos , Agências Internacionais/economia , Agências Internacionais/organização & administração , Malária/prevenção & controle , Área Carente de Assistência Médica , Objetivos Organizacionais/economia , Resultado do Tratamento , Organização Mundial da Saúde/economia , Organização Mundial da Saúde/organização & administraçãoRESUMO
OBJECTIVE: To present a repeated test of the quality of ampicillin, tetracycline, chloroquine and ASA from private pharmacies in Laos in 1997 and 1999, and to discuss the quality in relation to the National Drug Policy Programme. METHOD: A total of 115 of 214 licensed private pharmacies were selected in Savannakhet province, a pilot province in the Lao National Drug Policy Programme. The four drugs, if available, were collected at each pharmacy. Thirty tablets of each drug were taken from a selected container. In 1997, 366 samples were analysed and three hundred in 1999. Identity, assay (content of active component) and measurement of weight variation tests were performed. Drug quality was compared mainly according to the standards of the British and United States' pharmacopoeias. RESULTS: The percentage of substandard drugs decreased significantly from 46% to 22% between 1997 and 1999 (P< 0.001). Substandard ampicillin and tetracycline were reduced significantly from 67% to 9% and from 38% to 12%, respectively (P < 0.001). In total, 3% vs 1% contained no active ingredient, 12% vs 4% had too little or too much active ingredient, and 35% vs 14% had weight variation outside pharmacopoeial limits. CONCLUSION: Drug quality was improved. However, the prevalence of substandard drugs was still unacceptably high, which may result in adverse clinical effect or treatment failure for individual patients.
Assuntos
Preparações Farmacêuticas/normas , Assistência Farmacêutica/normas , Ampicilina/normas , Antibacterianos/normas , Anti-Inflamatórios não Esteroides/normas , Antimaláricos/normas , Aspirina/normas , Cápsulas , Cloroquina/normas , Laos , Farmacopeias como Assunto/normas , Setor Privado , Garantia da Qualidade dos Cuidados de Saúde , Controle de Qualidade , Comprimidos , Tetraciclina/normasRESUMO
BACKGROUND: Antimalaria treatment failure has been partly attributed to poor quality antimalarials in the drug market. A 1998 survey in Kampala showed that 55% of tablets and 62% of injection forms of chloroquine failed the quality test. OBJECTIVE: This study was carried out as a follow-up to establish the quality of chloroquine tablet and injection dosage forms in the Ugandan drug market from June - November 2001. METHODS: Chloroquine tablets and injection dosage forms, randomly purchased from pharmacies and drug shops in the four regions of Uganda, were assayed for content of the active ingredient according to the USP standard, using the HPLC method. RESULTS: Of the tablets samples surveyed, 39% failed the content test with 11% having sub-normal and 28% having supra-normal amounts, whilst 51% of the injection samples failed with 40% and 11% having sub-normal and supra-normal amounts respectively. CONCLUSION: There was overall improvement in the quality of chloroquine in Uganda compared with the 1998 figures, but the failure rates are still unacceptably high. The variations in the chloroquine amounts in both the tablet and injection forms may contribute to chloroquine toxicity or poor response during treatment. More vigorous pharmacovigilance on drugs entering the Ugandan drug market is needed.
Assuntos
Antimaláricos/química , Antimaláricos/normas , Cloroquina/química , Cloroquina/normas , Cromatografia Líquida de Alta Pressão , Estudos Transversais , Controle de Medicamentos e Entorpecentes , Humanos , Injeções , Controle de Qualidade , Comprimidos , UgandaRESUMO
The efficacy and tolerability of single, low-dose mefloquine, sulfadoxine-pyrimethamine (MSP) combination was compared with chloroquine (CQ) for malaria treatment in a malaria-endemic area of Nigeria with multiple drug-resistant Plasmodium falciparum. The two drug regimens (MSP and CQ) were tested in a 12-month prospective population study. The patients were divided into two groups. Group 1 patients were treated presumptively, based on malaria symptoms. Group 2 patients were treated based on a parasitologic diagnosis using the World Health Organization seven-day in vivo test and extended to a 28-day follow-up period. Tolerability was assessed by the incidence and intensity of adverse events. One thousand nine hundred thirty-five patients visiting 10 health facilities, including the University of Calabar Teaching Hospital, were enrolled. The study showed that the low-dose MSP was efficacious, with day 7 response rates of 95% and 91% for (presumptive) Group 1 and (in vivo) Group 2, respectively, while CQ had day 7 response rates of 82% and 66% in Groups 1 and 2, respectively. The low-dose MSP was significantly (P < 0.0001) more efficacious, with faster fever and parasite clearance times than CQ in this area of CQ-resistant P. falciparum malaria. Eight patients treated with CQ, including seven severe cases (RII-RIII) were successfully re-treated with MSP. Adverse events were generally more common among those treated with MSP (29%) than those treated with CQ (17%). However, the adverse events caused by both drugs were mild to moderate and self-limited. The MSP combination appears to be a good substitute for CQ, in view of multiple drug resistance, especially in areas with severe (RII-RIII) malaria.
Assuntos
Antimaláricos/uso terapêutico , Cloroquina/uso terapêutico , Resistência a Múltiplos Medicamentos , Malária Falciparum/tratamento farmacológico , Mefloquina/análogos & derivados , Plasmodium falciparum/efeitos dos fármacos , Pirimetamina/uso terapêutico , Sulfadoxina/uso terapêutico , Adolescente , Adulto , Animais , Antimaláricos/administração & dosagem , Antimaláricos/efeitos adversos , Antimaláricos/normas , Sangue/parasitologia , Criança , Pré-Escolar , Cloroquina/administração & dosagem , Cloroquina/efeitos adversos , Cloroquina/normas , Combinação de Medicamentos , Feminino , Humanos , Lactente , Masculino , Mefloquina/administração & dosagem , Mefloquina/efeitos adversos , Mefloquina/normas , Mefloquina/uso terapêutico , Pessoa de Meia-Idade , Nigéria , Estudos Prospectivos , Pirimetamina/administração & dosagem , Pirimetamina/efeitos adversos , Pirimetamina/normas , Distribuição Aleatória , Sulfadoxina/administração & dosagem , Sulfadoxina/efeitos adversos , Sulfadoxina/normasRESUMO
Malaria remains an important public health problem in Uganda. The mainstay of treatment is still chloroquine. However, recently there have been several reports of poor response to chloroquine treatment. We do not know whether the reported poor response is due to true resistance or poor quality of the drug in the market. This study was done to assess the quality of chloroquine dosage forms in Kampala. The study was cross-sectional; end-point designed to assess the amount of the active ingredient in the tablet and injection dosage forms of the drug. The quality assay was based on the BP, 1988 standard, using both visual and potentiometric analysis technique. The study demonstrated that there is a problem with the quality of chloroquine in the market. Upto 30% of the tablet samples and 33% of injection samples contained less than the stated amount of the active ingredient. This may be one of the reasons for the reported poor response of malaria to chloroquine treatment in Uganda. Given that routine laboratory testing of active ingredients in pharmaceuticals is not practised in Uganda, this study has demonstrated the necessity for establishment of a drug quality control laboratory in the country.
Assuntos
Antimaláricos/química , Antimaláricos/normas , Cloroquina/química , Cloroquina/normas , Administração Oral , Antimaláricos/provisão & distribuição , Cloroquina/provisão & distribuição , Estudos Transversais , Controle de Medicamentos e Entorpecentes , Humanos , Injeções , Potenciometria , Controle de Qualidade , Comprimidos , UgandaRESUMO
In this paper the percentage purity, active ingredients, specific gravity and the pH of paracetamol and chloroquine syrups were determined. For paracetamol the percentage purity ranged from 102.6-106.67, while the active ingredients (in mg/5 ml base) ranged from 123.2-128. The specific gravity ranged from 1.13-1.24 and the pH from 4.16-5.32. For the chloroquine the percentage purity ranged from 97-106.3, and the active ingredient 48.5-53.13, the specific gravity 1.17-1.27 and the pH 2.44-4.17. The results are discussed in relation to the purity, active ingredients and sources of the drugs. The drugs were coded. The paracetamol had a code of 1p-5p while the chloroquine was coded from 1c-5c.
Assuntos
Acetaminofen/normas , Cloroquina/normas , Medicamentos sem Prescrição/normas , Acetaminofen/administração & dosagem , Acetaminofen/química , Acetaminofen/provisão & distribuição , Administração Oral , Cloroquina/administração & dosagem , Cloroquina/química , Cloroquina/provisão & distribuição , Contaminação de Medicamentos , Concentração de Íons de Hidrogênio , Nigéria , Medicamentos sem Prescrição/administração & dosagem , Medicamentos sem Prescrição/química , Medicamentos sem Prescrição/provisão & distribuição , Controle de Qualidade , Gravidade Específica , Equivalência TerapêuticaRESUMO
In Third World countries chloroquine phosphate syrup is frequently prepared with chloroform as a preservative. Because of the toxic side effects of chloroform the suitability of a number of possible alternatives were investigated. If the chloroquine phosphate syrup is prepared as such, the combination of sorbic acid (1.5 g/l) and citric acid (2 g/l) is preferred. If, however, the chloroquine phosphate syrup is prepared from a stock solution of simple syrup, the relatively low pH may be undesirable, because it may negatively affect the stability or solubility of other medicinal compounds. For a stock solution of simple syrup the combination of methyl paraben (1.8 g/l) and propyl paraben (0.2 g/l) is preferred. Good care must be taken that a layer of condense water cannot be formed.
Assuntos
Antimaláricos/normas , Cloroquina/análogos & derivados , Excipientes Farmacêuticos/normas , Conservantes Farmacêuticos/normas , Administração Oral , Cloroquina/normas , Países em Desenvolvimento , Estabilidade de Medicamentos , HumanosRESUMO
The disintegration, dissolution and bio-availability characteristics of six of the most popular brands of chloroquine used in Nigeria were determined in order to test the hypothesis that there are no significant differences among the different brands. The disintegration times of all the six brands ranged from 8.9 to 40.4 min while the dissolution times ranged from 17.5 to 60 min. All passed the U.S. Pharmacopoiea (USP) XX disintegration test. Bio-availability studies done on two brands, Avloclor (ICI) with the fastest dissolution rate and Pfizerquine (Pfizer) with the slowest dissolution rate, showed similar areas under the curve (AUC). Furthermore, their peak height concentration (Cmax) and time of peak height concentration (Tmax) did not show any significant differences. Consequently, statements about any of these six brands of cloroquine having a greater efficacy than the other may be pure conjecture.